Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents

Cancer
Frédéric MillotFrançois Guilhot

Abstract

In the adult population with newly diagnosed chronic myeloid leukemia (CML), variant translocations are usually not considered to be impairing the prognosis, whereas some additional cytogenetic abnormalities (ACAs) are associated with a negative impact on survival. Because of the rarity of CML in the pediatric population, such abnormalities have not been investigated in a large group of children with CML. The prognostic relevance of variant t(9;22) and ACAs at diagnosis was assessed in 301 children with CML in the chronic phase who were enrolled in the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. Overall, 19 children (6.3%) presented with additional cytogenetic findings at diagnosis: 5 children (1.7%) had a variant t(9;22) translocation, 13 children (4.3%) had ACAs, and 1 had both. At 3 years, for children with a classic translocation, children with ACAs, and children with a variant t(9;22) translocation who were treated with imatinib as frontline therapy, the probability of progression-free survival (PFS) was 95% (95% confidence interval [CI], 91%-97%), 100%, and 75% (95% CI, 13%-96%), respectively, and the probability of overall survival (OS) was 98% (95% CI, 95%-100%), 100% (95% CI, 43%-98...Continue Reading

References

Jul 15, 1976·International Journal of Cancer. Journal International Du Cancer·F MitelmanL Brandt
Jan 1, 1987·Cytogenetics and Cell Genetics·M De Braekeleer
Jan 1, 1993·Leukemia & Lymphoma·F Mitelman
Apr 29, 2003·British Journal of Haematology·Alistair G ReidElisabeth P Nacheva
Apr 3, 2004·British Journal of Haematology·Maha M T El-ZimaityJorge E Cortes
Feb 27, 2007·Cancer Genetics and Cytogenetics·Madhavi GorusuMin Fang
Jan 12, 2010·Bone Marrow Transplantation·L ScruccaF Aversa
Mar 31, 2011·Blood·Giulia MarzocchiUNKNOWN Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on Chronic Myeloid Leukemia
Jun 28, 2011·Blood·François Guilhot
Nov 1, 2011·Blood·Alice FabariusUNKNOWN Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group
Jun 14, 2012·Blood·Simona LuattiUNKNOWN Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML
Jun 4, 2016·Blood·François Guilhot

❮ Previous
Next ❯

Citations

Nov 16, 2018·Journal of Cellular Physiology·Ali Amin AsnafiTina Vosughi
Mar 29, 2019·Blood·Nobuko Hijiya, Meinolf Suttorp
Aug 1, 2020·British Journal of Haematology·Graeme SmithUNKNOWN British Society for Haematology
Oct 28, 2017·Expert Review of Clinical Pharmacology·Meinolf SuttorpEberhard Schleyer
Sep 3, 2020·World Journal of Clinical Oncology·Meinolf SuttorpFrédéric Millot
Nov 20, 2019·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Amro Mohamed Sedky El-GhammazMohamed Osman Azzazi
May 15, 2019·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Frédéric MillotMeinolf Suttorp

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.